Pharmaceutical Product Development, LLC (PPD) has entered into an agreement to acquire Evidera, a provider of evidence-based solutions to demonstrate real-world effectiveness and value of biopharmaceutical products. The acquisition expands PPD’s peri- and post-approval capabilities. The acquisition, subject to certain closing conditions, is expected to close in 3Q16.   Evidera will become a wholly owned subsidiary of PPD, providing peri- and post-approval studies, health economics, outcomes re...